Medtronic, Inc. & Consolidated Subsidiaries v. Commissioner of Internal Revenue

Case Overview (U.S. Tax Court 2016)

In Medtronic, Inc. & Consolidated Subsidiaries v. Commissioner (T.C. Memo. 2016-112), the U.S. Tax Court evaluated the arm’s-length royalty for intangibles licensed within Medtronic’s group to support the Puerto Rico manufacture of Class III implantable medical devices and leads. The court rejected the IRS’s CPM-based reallocations as arbitrary and instead derived its own royalty rates using a CUT framework with adjustments. (The Eighth Circuit later vacated and remanded for more complete findings. Medtronic II, 900 F.3d 610 (8th Cir. 2018).)

Key Facts

• Years at issue: 2005–2006.
• Manufacturing entity: Medtronic Puerto Rico Operations Co. (MPROC) manufactured Class III finished devices and leads in a highly regulated environment.
• Intercompany pricing dispute: Medtronic defended its device and lead royalties using a CUT anchored principally to the third-party Pacesetter license/settlement; the IRS asserted CPM (a TNMM analogue) with MPROC as the tested party.
• Audit history mattered: A prior IRS–taxpayer memorandum of understanding (from a 2002 audit) used compromise royalty rates (44% devices; 26% leads), but later audits did not settle the 2005–2006 outcome. (Medtronic II, slip op. at 2–4.)
• IRS amounts asserted (amended): deficiencies of $548,180,115 (2005) and $810,301,695 (2006). (Medtronic II, slip op. at 3–4.)
• Tax Court’s rates: 44% wholesale royalty for devices and 22% for leads, and it applied 44% to the Swiss supply agreement device sales. (EY summary; Medtronic II, slip op. at 4.)

What Was Being Decided

The court addressed (among other issues) whether the Commissioner’s §482 reallocations—built on a CPM/value-chain analysis—were reasonable, and if not, what arm’s-length royalties should apply under the “best method” rule. The IRS also advanced an alternative §367(d) theory tied to prior restructuring, which the Tax Court rejected. (EY summary.)

Holding (and What the Court Did With Competing Methods)

1) IRS CPM reallocations rejected as arbitrary/capricious

The Tax Court found the Commissioner’s allocations “arbitrary, capricious, or unreasonable,” criticizing core elements of the IRS analysis, including the treatment of MPROC’s role in quality control, comparables selection, the return-on-assets approach, aggregation, and failure to account for licensed intangibles. (Medtronic II, slip op. at 4 (summarizing Tax Court findings).)

2) Taxpayer’s CUT not accepted as presented

Although the Tax Court viewed a CUT approach as the most reliable directionally, it found Medtronic’s CUT work inadequate (e.g., lack of persuasive adjustments and inadequate separation of devices vs. leads), so the court recomputed the royalty result itself rather than adopting the taxpayer’s proposed rates. (EY summary; Medtronic II, slip op. at 4.)

3) Court-imposed royalty rates and tax result

The Tax Court determined wholesale royalty rates of 44% (devices) and 22% (leads). After Rule 155 computations, the court entered an income tax deficiency of $26,711,582 for 2005 and an overpayment of $12,459,734 for 2006 (order entered Jan. 25, 2017). (Medtronic II, slip op. at 4, 8.)

What Happened on Appeal (Why Medtronic I Was Vacated)

The Eighth Circuit vacated and remanded because the Tax Court’s findings were not detailed enough to review whether the Pacesetter agreement was truly comparable and how key differences were handled—particularly that it arose from litigation and included a lump-sum payment, cross-licenses, and different treatment of non-patent intangibles/know-how. The appellate court also faulted the absence of a specific finding allocating risk and product-liability expense between the U.S. and Puerto Rico operations. (Medtronic II, slip op. at 5–8.)

Takeaways for Practitioners

• CUTs can win “best method” battles—but only with rigorous comparability work (contract terms, covered intangibles, profit potential, and necessary adjustments).
• Litigation-settlement licenses are not automatically unusable, but courts (and appellate courts) may demand explicit analysis of settlement dynamics, lump sums, and cross-licensing. (Medtronic II, slip op. at 6–8.)
• “Quality” and regulated-manufacturing functions can be profit-relevant, but risk allocation must be supported with evidence and quantified findings, not just general narratives.
• When both sides’ analyses fail, courts may construct their own pricing, increasing outcome uncertainty.

Related Content

For practical guidance on supporting IP royalties, see Documentation for Intangibles and Benchmarking Study Guide. Core concepts include Comparable Uncontrolled Price and Transactional Net Margin Method. Follow-on proceedings are discussed in Medtronic II and III.

Frequently Asked Questions

Q1: What transfer pricing methods were at issue in Medtronic I?
Medtronic primarily relied on a CUT (based largely on the Pacesetter agreement). The IRS asserted CPM with MPROC as the tested party. (Medtronic II, slip op. at 3–4.)

Q2: Why did the Tax Court reject the IRS’s CPM approach?
As summarized by the Eighth Circuit, the Tax Court criticized the IRS analysis for undervaluing MPROC’s quality role and for issues involving comparables, return-on-assets calculations, aggregation, and ignoring licensed intangibles. (Medtronic II, slip op. at 4.)

Q3: What royalty rates did the Tax Court set?
44% (devices) and 22% (leads) as wholesale royalties; 44% was also applied to the Swiss supply agreement device sales. (EY summary; Medtronic II, slip op. at 4.)

Q4: Did Medtronic “win” after the Tax Court recomputed the royalties?
Relative to the IRS’s amended asserted deficiencies (over $1.3B across both years), the Tax Court outcome was far smaller. But the court also did not accept Medtronic’s requested pre-MOU CUT rates and instead imposed its own rates. (EY summary; Medtronic II, slip op. at 3–4.)

Q5: Why did the Eighth Circuit remand the case?
The Eighth Circuit found the Tax Court’s comparability findings insufficient—especially regarding the Pacesetter agreement’s litigation context, lump sum, cross-licenses, and excluded intangibles—and required clearer findings on risk/product-liability allocation. (Medtronic II, slip op. at 5–8.)